Clinical Trial Update: Safety and Efficacy of Autologous Mesenchymal Stem Cells in Chronic Spinal Cord Injury [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating autologous mesenchymal stem cells for spinal cord injury has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Cord Injury

Drugs mentioned

• Autologous mesenchymal stem cells (mesenchymal stem cells)

Snippet

Sponsor: Pharmicell Co., Ltd. | Conditions: Spinal Cord Injury | Phase 2, Phase 3 | Status: TERMINATED